Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls

Nutrition

Volumn 16, Issue 6, 2000, Pages 434-438

  Bunout, Daniel ^a   Petermann, Margarita ^a   Hirsch, Sandra ^a   De La Maza, Pía ^a   Suazo, Myriam ^a   Barrera, Gladys ^a   Kauffman, Ronald ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Atherosclerosis; Cardiovascular disease; Folate; Homocysteine

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALPHA TOCOPHEROL; CHOLESTEROL; CREATININE; CYANOCOBALAMIN; FOLIC ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; TRIACYLGLYCEROL;

ADULT; AGE; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DEMOGRAPHY; DISEASE ASSOCIATION; ERYTHROCYTE VOLUME; FEMALE; FOLIC ACID BLOOD LEVEL; GENETIC DISORDER; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; VITAMIN BLOOD LEVEL;

AGED; ARTERIOSCLEROSIS; CHOLESTEROL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY DISEASE; FEMALE; FOLIC ACID; FOLIC ACID DEFICIENCY; HOMOCYSTEINE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES; VITAMIN B 12; VITAMIN E;

EID: 0034043191     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(00)00289-6     Document Type: Article

References (35)

1. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia an independent risk factor for vascular disease. N Engl J Med. 324:1991;1149.
2. Nygard O., Nordrehaug J.E., Refsum H., et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 337:1997;230.
3. Kang S.S., Zhou J., Wong P.W.K., Kowalisyn J., Strokosch G. Intermediate homocysteinemia a thermolabile variant of methylentetrahydrofolate reductase. Am J Hum Genet. 43:1988;414.
4. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 10:1995;111.
5. Brattstrom L., Wilcken D.E.L., Ohrvik J., Brudin L. Common methylentetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. Circulation. 98:1998;2520.
6. McQuillan B.M., Beilby J.P., Nidorf M., Thompson P.L., Hung J. Hyperhomocysteinemia but not the C677T mutation of methylentetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. Circulation. 99:1999;2383.
7. Malinow M.R., Duell P.B., Hess D.L., et al. Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 338:1998;1009.
8. 12 deficiency after gastric surgery. Ann Intern Med. 124:1996;469.
9. 6 status on homocysteine metabolism. J Clin Invest. 98:1996;177.
10. Donner M.G., Klein G.K., Mathes P.B., Schwandt P., Richter W.O. Plasma total homocysteine levels in patients with early onset coronary heart disease and low cardiovascular risk profile. Metabolism. 47:1998;273.
11. Evans R.W., Shaten J., Hempel J.D., Cutler J.A., Kuller L.H. Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler Thromb Vasc Biol. 17:1997;1947.
12. Folsom A.R., Nieto J., McGovern P.G., et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms and B vitamins. Circulation. 98:1998;204.
13. de Jong S.C., Stehouwer C.D.A., Mackaay A.J.C., et al. High prevalence of hyperhomocysteinemia and asymptomatic vascular disease in siblings of young patients with vascular disease and hyperhomocysteinemia. Arterioscler Thromb Vasc Biol. 17:1997;2655.
14. Ubbink J.B., Vermaak J.H., Bissbort S. Rapid high performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 565:1991;441.
15. Lehmann J., Martin H.L. Improved direct determination of alpha and gamma tocopherols in plasma and platelets by liquid chromatography, with fluorescence detection. Clin Chem. 28:1982;1784.
16. Firedman J.A., Dwyer T.D. Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing dialysis. Nutr Rev. 53:1995;197.
17. Lussier-Cacan S., Xhignesse M., Piolot A., et al. Plasma total homocysteine in healthy subjects sex specific relation with biological traits. Am J Clin Nutr. 64:1996;587.
18. Rolland P.H., Friggi A., Barlatier A., et al. Hyperhomocysteinemia induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation. 91:1995;1161.
19. Demuth K., Moatti N., Hanon O., et al. Opposite effect of plasma homocysteine and the methylentetrahydrofolate reductase C677T mutation on carotid artery geometry in asymptomatic adults. Arterioscler Thromb Vasc Biol. 18:1998;1838.
20. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest. 98:1996;5.
21. Hirano K., Ogihara T., Miki M., et al. Homocysteine induces iron catalized lipid peroxidation of low-density lipoprotein that is prevented by alpha tocopherol. Free Rad Res. 21:1994;267.
22. Harpel P.C., Zhang X., Borth W. Homocysteine and hemostasis pathogenetic mechanisms predisposing to thrombosis. J Nutr. 126:1996;1285S.
23. Rodgers G.M., Kane W.H. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 77:1986;1909.
24. Lentz S.R., Sadler J.E. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 88:1991;1906.
25. Harpel P.C., Borth W. Identification of mechanisms that may modulate the role of lipoprotein(a) in thrombosis and atherogenesis. Ann Epidemiol. 2:1992;413.
26. Fermo I., Vigano S., Paroni R., et al. Prevalence of moderate hyperhomocysteinemia in patients with early onset venous and arterial occlusive disease. Ann Intern Med. 123:1995;747.
27. Egerton W., Silberberg J., Crooks R., Ray C., Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol. 77:1996;759.
28. Lindgren A., Brattstrom L., Norrving B., et al. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 26:1995;795.
29. Ueland P.M., Refsum H., Stabler S.P., et al. Total homocysteine in plasma or sera methods and clinical application. Clin Chem. 39:1993;1764.
30. Verhaar M.C., Wever R.M.F., Kastelein J.J.P., et al. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation. 97:1998;237.
31. Stroes E., Kastelein J., Cosentino F., et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 99:1997;41.
32. Kaufman S. Some metabolic relationships between biopterin and folate implications for the "methyl trap hypothesis. " Neurochem Res. 16:1991;1031.
33. Bottiglieri T., Hyland K., Laundy M., et al. Folate deficiency, biopterin and monoamine metabolism in depression. Psychol Med. 22:1992;871.
34. Abbate R., Sardi I., Pepe G., et al. The high prevalence of thermolabile 5-10 methylentetrahydrofolate reductase in Italians is not associated to an increase risk for coronary artery disease. Thromb Haemostat. 79:1998;727.
35. Harmon D.L., Doyle R.M., Meleady R., et al. Genetic analysis of the thermolabile variant of 5-10 methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. Arterioscler Thromb Vasc Biol. 99:1999;208.